For research use only. Not for therapeutic Use.
Eclitasertib (Cat.No:I026698) is an investigational anticancer compound. It functions as a selective inhibitor of the enzyme DNA-dependent protein kinase (DNA-PK), which is involved in DNA repair processes. Eclitasertib shows potential in the treatment of various cancers and is currently undergoing preclinical and clinical studies to evaluate its efficacy and safety.
Catalog Number | I026698 |
CAS Number | 2125450-76-0 |
Synonyms | Eclitasertib; Eclitasertibum; |
Molecular Formula | C19H18N6O3 |
Purity | 98% |
Target | RIP kinase |
Solubility | Soluble in DMSO |
Appearance | Solid powder |
Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
IUPAC Name | 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydropyrido[3,2-b][1,4]oxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide |
InChI | InChI=1S/C19H18N6O3/c1-25-17-14(8-5-9-20-17)28-11-13(19(25)27)21-18(26)16-22-15(23-24-16)10-12-6-3-2-4-7-12/h2-9,13H,10-11H2,1H3,(H,21,26)(H,22,23,24)/t13-/m0/s1 |
InChIKey | XUZICJHIIJCKQQ-ZDUSSCGKSA-N |
SMILES | CN(C([C@](NC(C1=NC(CC2=CC=CC=C2)=NN1)=O)([H])CO3)=O)C4=C3C=CC=N4 |